Quantcast
Home » News » Justice
Home » News » Justice

Allergan reviews meeting requests in takeover bid

First Published Aug 23 2014 11:53AM      Last Updated Aug 23 2014 12:22 pm

Irvine, Calif. • Botox maker Allergan says it’s reviewing shareholder requests for a special meeting to consider replacing most of its board.

That’s a change fellow drugmaker Valeant Pharmaceuticals is seeking as part of its hostile takeover attempt.

Allergan has repeatedly rejected Valeant’s offers to buy the company, the latest for about $53 billion, saying Valeant is substantially undervaluing the company and that an independent Allergan can generate more value for shareholders.

Valeant and its partner — investment fund manager Pershing Square — said late Friday they submitted to Allergan written requests from its shareholders of 31 percent of Allergan’s stock requesting a special meeting of Allergan shareholders.



Allergan says it will announce details on a possible meeting once it finishes reviewing the requests. Valeant says it believes Allergan must hold that meeting by Dec. 20.

 

 

 

 

comments powered by Disqus